Henoch–Schönlein purpura and recurrent renal failure

Vonend, Catharina; Rifkin, Stephen I.; Baliga, Rajendra; Weinstein, Stefanie

doi:10.3109/0886022x.2010.494793

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been 51 reported cases of HSP where MMF has been used as immunosuppressive therapy, mostly in patients diagnosed with HSP nephritis, 21 of which describe pediatric patients. 2-10 A recent retrospective analysis compared 27 patients with HSP nephritis treated with MMF (1-1.5 g/d) and low-dose prednisone (0.4-0.5 mg/kg/d) with 26 patients treated with high-dose corticosteroids (0.8-1.0 mg/kg/d). 2 This study suggested that MMF may be beneficial for the induction and maintenance of remission of HSP nephritis with a significant reduction in adverse events.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Henoch-Schönlein Purpura With Recurrent Gastrointestinal Involvement With Mycophenolate Mofetil

Chou

Louissant

Adams

et al. 2015

Clin Pediatr (Phila)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Henoch-Schönlein Purpura With Recurrent Gastrointestinal Involvement With Mycophenolate Mofetil

Chou

Louissant

Adams

et al. 2015

Clin Pediatr (Phila)

View full text Add to dashboard Cite

“…No randomized trials have been reported, and published series using TPE have included more cases of HSP than IgA nephropathy. Although the literature may be colored by a positive publication bias, there are several series and cases where outcomes appear to improve with TPE use (44–47). Using TPE as the sole treatment to avoid drug side effects in children has also shown benefits compared with historical controls (42,44).…”

Section: Iga Nephropathy and Henoch–schonlein Nephritismentioning

confidence: 99%

Therapeutic Apheresis for Renal Disorders

Sanchez

Ward

2012

Seminars in Dialysis

View full text Add to dashboard Cite

This review summarizes the clinical evidence and practical details for the use of plasmapheresis and other apheresis modalities for each indication in nephrology. Updated information on the molecular biology and immunology of each renal disease is discussed in relation to the rationale for apheresis therapy and its place amid other available treatments. Autoantibody-mediated diseases, such as anti-GBM (anti-glomerular basement membrane) glomerulonephritis (GN), ANCA (antineutrophil cytoplasmic antibody)-related GN and the antibody-mediated type of TTP (thrombotic thrombocytopenic purpura), and alloantibody-mediated diseases such as kidney transplant sensitization and humoral rejection, can be treated by various plasmapheresis methods. These include standard plasmapheresis with a replacement volume, or plasmapheresis with online plasma purification using adsorption columns or secondary filtration. However, it should be noted that the pathogenic molecules implicated in FSGS (focal segmental glomerulosclerosis), myeloma cast nephropathy, and perhaps other diseases are too small to be removed by most online purification methods. A great majority of controlled trials and series on which evidence-based treatment recommendations are made were performed using centrifugal plasmapheresis; it is presumed that membrane-separation plasmapheresis is equally efficacious. For some rarer diseases, such as MPGN (membranoproliferative GN) type 2 with factor H abnormalities or C3Nef (C3 nephritic factor) autoantibodies, there are only a few case reports, but enough scientific understanding to warrant a trial of plasmapheresis in severe cases. Photopheresis, which is effective for cell-mediated rejection in heart and lung transplantation, has not yet found a place in the routine treatment of kidney transplant rejection.

show abstract

“…Vonend et al [60] reported an 18-year-old male who suffered from several incidents of acute renal failure secondary to HSP. The patient underwent hemodialysis for 2 months following the initial episode of renal failure and recovered shortly after the onset of the second episode.…”

Section: Treatmentmentioning

confidence: 99%

Urological Manifestations of Henoch-Schonlein Purpura: A Review

et al. 2015

View full text Add to dashboard Cite

Henoch-Schonlein purpura (HSP) is an immune-mediated systemic vasculitis generally found in children. The standard manifestations of HSP are palpable purpura, arthritis, abdominal pain, and renal complications. Although less common, there are significant urological manifestations associated with HSP. The primary objective of this review is to encourage better understanding and management of HSP by emphasizing the common and rare manifestations of HSP, how they are diagnosed, and the latest treatment options for mild to severe complications. Medline searches of HSP and its urological manifestations were conducted along with searches on current diagnostic and treatment methods. Urological manifestations of HSP involve the kidney, ureter, bladder, prostate, scrotum, testicle, and penis. Diagnosis and management of HSP are not always clear due to differential diagnosis and diversity of symptom presentation. Treatment for HSP is mainly supportive and includes use of nonsteroidal anti-inflammatory drugs for pain relief. In more severe cases, glucocorticoids, methylprednisolone, plasmapheresis, and peritoneal and hemodialysis are reported successful. It is important to note different symptoms of HSP in order to distinguish HSP from other diseases. Early diagnosis may prevent severe complications. Treatment options vary from conservative to invasive depending on the severity of the disease and time frame of diagnosis.

show abstract

Henoch–Schönlein purpura and recurrent renal failure

Cited by 6 publications

References 14 publications

Successful Treatment of Henoch-Schönlein Purpura With Recurrent Gastrointestinal Involvement With Mycophenolate Mofetil

Successful Treatment of Henoch-Schönlein Purpura With Recurrent Gastrointestinal Involvement With Mycophenolate Mofetil

Therapeutic Apheresis for Renal Disorders

Urological Manifestations of Henoch-Schonlein Purpura: A Review

Contact Info

Product

Resources

About